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Abstract
Background: Streptozotocin-induced diabetes (STZ-D) in rats has been associated with carnitine
deficiency, bradycardia and left ventricular enlargement.
Aim: The purpose of this study was to determine whether oral carnitine supplementation would
normalize carnitine levels and cardiac function in STZ-D rats.
Methods: Wistar rats (48) were made hyperglycemic by STZ at 26 weeks of age. Same age normal
Wistar rats (24) were used for comparison. Echocardiograms were performed at baseline 2, 6, 10,
and 18 weeks after STZ administration in all animals. HbA1c, serum carnitine and free fatty acids
(FFA) were measured at the same times. Since STZ-D rats become carnitine deficient, 15 STZ-D
rats received supplemental oral carnitine for 16 weeks.
Results: The heart rates for the STZ-D rats (290 ± 19 bpm) were less than control rats (324 ± 20
bpm) (p < 0.05). After 4 weeks of oral carnitine supplementation, the serum carnitine and heart
rates of the STZ-D rats returned to normal. Dobutamine stress increased the heart rates of all
study animals, but the increase in STZ-D rats (141 ± 8 bpm) was greater than controls (79 ± 8 bpm)
(p < 0.05). The heart rates of STZ-D rats given oral carnitine, however, were no different than
controls (94 ± 9 bpm). The left ventricular mass/body weight ratio (LVM/BW) in the diabetic
animals (2.7 ± 0.5) was greater than control animals (2.2 ± 0.3) (p < 0.05) after 18 weeks of
diabetes. In contrast, the LVM/BW (2.3 ± .2) of the STZ-D animals receiving supplemental carnitine
was the same as the control animals at 18 weeks.
Conclusion: Thus, supplemental oral carnitine in STZ-D rats normalized serum carnitine, heart
rate regulation and left ventricular size. These findings suggest a metabolic mechanism for the
cardiac dysfunction noted in this diabetic animal model.
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Background
Cardiovascular disease is the most common serious com-
plication of diabetes mellitus. Coronary atherosclerosis
and cardiomyopathy occur as a result of the metabolic
abnormalities associated with diabetes [1]. These physical
changes require years to develop in humans following the
onset of chronic hyperglycemia [2]. We have previously
shown that cardiac function is altered after 6 months of
hyperglycemia in Wistar rats [3]. We and others [4,5] have
noted bradycardia to be a consistent feature when evalu-
ating diabetic rat models. Heart rate variability in diabetes
is commonly attributed to associated neuropathy [6]. It
has been noted, however, that the induction of hypergly-
cemia after 6 months of life in Wistar rats does not alter
peripheral nerve function for an additional 6 months [7].
Carnitine deficiency is often encountered in diabetes mel-
litus [7,8]. Structural changes in myocardial mitochondria
have been associated with diabetes and concomitant car-
nitine deficiency [3]. In the current study, the evaluation
of cardiac functional changes in Wistar rats began with the
induction of hyperglycemia at 6 months of age and was
monitored on a monthly basis for an additional 18 weeks.
The first objective of this study was to observe the evolu-
tion of cardiac dysfunction in streptozotocin diabetic
(STZ-D) rats to help understand its pathogenesis. Sec-
ondly, the effect of carnitine supplementation upon the
cardiac dysfunction of diabetes in these animals was eval-
uated.
Methods
Male Wistar rats at 26 weeks of age were entered into this
study. There was one animal per cage, and each had free
access to food and water. The water bottles were filled
twice each day and the animals were weighed once each
week to insure weight gain and appropriate hydration.
Hyperglycemia was induced in 48 animals at 26 weeks of
age by the intraperitoneal injection of STZ (35 mg/kg)
buffered in cold sodium citrate (pH 4.5). The current
investigation conformed to the Guide for the Care and
Use of Laboratory Animals [9], and was approved by the
Institutional Animal Care and Use Committee at the Uni-
versity of South Florida. Seven days after STZ injection,
hyperglycemia was documented by measuring the glucose
content of tail vein blood with an Ames Glucometer 2
(Bayer Laboratories, Elkhart, IN, USA). Hyperglycemia
was defined as plasma glucose greater than 16.7 mmol/L.
Subsequent tests for hyperglycemia were performed at 2,
6, 10 and 18 weeks with blood glucose and Glycosylated
hemoglobin measurements. Glycosylated hemoglobin
(GHb) was determined by affinity chromatography using
Gly-Affin GHb columns (Isolab, Inc., Akron, OH, USA).
Plasma was also collected at the same time for the meas-
urement of free and total carnitine by a modification of a
radio-enzymatic method [10] and non-esterified free fatty
acids (FFA) were measured by the method of Duncombe
and Rising [11]. Ultra Lente insulin (Eli Lilly Co., Indian-
apolis, IN, USA) was injected subcutaneously three times
a week at a dose (3–5 units/kg) designed to promote
weight gain but inadequate to produce normal blood glu-
cose levels. After 2 weeks of hyperglycemia, sixteen of the
forty-eight diabetic animals had L-carnitine (1 mg/ml)
(Sigma Tau, Rome, Italy) added to their drinking water for
the duration of the study. Echocardiographic measure-
ments were recorded as previously described [3] at base
line, 2, 6, 10, and 18 weeks. Twenty-four normal animals
the same age served as comparative controls. One of the
diabetic + carnitine animals died during the first 2 weeks
of the protocol. Twelve of the 32 diabetic animals not
receiving carnitine died between the 10 and 18 week
measurements. Six animals from each group (control, dia-
betic, diabetic + carnitine) at 25 weeks had echocardio-
graphic measurements before and 5 minutes after the
intravenous administration of dobutamine (10 µg/kg/
min). All results are expressed as mean ± SEM. Group
means were compared, because of multiple measures, by
Bonferroni procedure [12]. Pearson correlation coeffi-
cients were used to evaluate the relationship of metabolic
parameters to the heart rates of these animals.
Results
Resting heart rates were reduced in diabetic rats (292 ± 10
bpm) when compared to controls (314 ± 9 bpm) (p <
0.05) after 2 weeks of diabetes. After 18 weeks of diabetes
the heart rates (290 ± 19 bpm) remained less than found
in the non diabetic control group (324 ± 20 bpm). The
free carnitine levels of the diabetic rats (19.1 ± 1.3) were
less than those found in control animals (43.7 ± 1.4) (p <
0.01). Carnitine supplementation of the diabetic rats for
16 weeks resulted in normal serum carnitine levels (54.8
± 4.4 nmol/ml) and heart rates (297 ± 22 bpm). The heart
rate decline was first noted 2 weeks after diabetes was
induced with STZ. The difference remained significant
during the 18 weeks of follow-up in the STZ-D animals.
However, the greatest difference in heart rates was noted
after 10 weeks of diabetes (259 ± 16 bpm) compared to
controls (307 ± 19 bpm). Twelve of the diabetic animals
died during the next 8 weeks and the heart rates of the sur-
viving 20 (290 ± 17 bpm) remained less than the non dia-
betic animals (324 ± 20 bpm), but not different from the
diabetic animals treated with supplemental carnitine (297
± 22 bpm). The 12 animals that died between 10 and 18
weeks had much lower heart rates (222 ± 19 vs. 281 ± 16)
(p < 0.008) and serum free carnitine (9.6 ± 3.3 vs. 24.2 ±
3.4) (p < 0.008) at 10 weeks than the STZ-D rats surviving
18 weeks. The STZ-D animals receiving carnitine in their
drinking water had mean heart rates begin to increase
after week 2 and returned to the non-diabetic control lev-
els by week 10 (figure 1). Dobutamine stress testing in 6
animals from each group resulted in increased heart rates.
The heart rate increase with the administration of dob-Cardiovascular Diabetology 2006, 5:2 http://www.cardiab.com/content/5/1/2
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utamine in the diabetic rats (141 ± 8 bpm) was greater
than controls (79 ± 9 bpm) (p < 0.05), but the heart rate
increase of diabetic rats receiving supplemental carnitine
(94 ± 9 bpm) did not differ from control animals.
The left ventricular mass/body weight ratio LVM/BW of
the diabetic animals (2.7 ± 0.5 gm/kg) was greater than
control animals (2.3 ± 0.4 gm/kg) (p < 0.05) after 18
weeks of diabetes. The weight of animals after 18 weeks of
diabetes was less than the control animals. The diabetic
animals receiving oral carnitine weighed the same as the
diabetic animals that did not receive carnitine (table 1)
but the LVM/BW (2.3 ± 0.2 gm/kg) was the same as the
control animals. The increase of left ventricular mass in
relation to body mass of the diabetic animals not receiv-
ing carnitine was greater during the 18 weeks of observa-
tion, but the weight gain of the diabetic animals was less
than the control animals. The increase of left ventricular
mass in the diabetic animals receiving oral carnitine was
not as great as the un-supplemented diabetic animals and
was more consistent with the increase in body mass for
those animals. The LVM/BW was greater than control val-
ues only for the diabetic animals with low serum carnitine
levels (figure 2). The control animals had a mean HbA1c
during the 18-week experiment of 5.9% ± 0.8 and the dia-
betic animals mean HbA1c was 10.9% ± 1.9 (p < 0.0001).
The mean HbA1c of the diabetic animals treated with oral
carnitine (10.6% ± 2.5), was similar to the diabetic ani-
mals not receiving carnitine. The heart rates of all of the
rats in this study not receiving supplemental carnitine
were inversely correlated to the HbA1c (r = -0.45, p =
0.0001) and directly correlated to the serum free carnitine
levels (r = 0.36, p <0.0001). The serum free carnitine levels
of the control and the diabetic animals without carnitine
supplementation were inversely related to HbA1c (r = -
0.33, p < 0.04); serum free carnitine in all of the study ani-
mals correlated inversely to the free fatty acid (FFA) levels
(r = -0.37, p < 0.02). The heart rate association to HbA1c
and serum free carnitine was not found in the normal con-
trol or diabetic animals receiving carnitine supplementa-
tion. The heart rates of the STZ-D animals, however,
Heart rate in beats/minute [BPM] [mean ± SD] at baseline,  2,6,10 and 18 weeks Figure 1
Heart rate in beats/minute [BPM] [mean ± SD] at baseline, 
2,6,10 and 18 weeks. * indicates values different from normal 
control values p < 0.05.
Table 1: Parameters after 18 weeks of STZ diabetes
Variables Control [24] Diabetic [20] Diabetic +Carnitine [15]
Weight [grams] 802 ± 74 711 ± 39* 715 ± 64*
LVM/BW [Gm/kg body weight] 2.3 ± 0.4 2.7 ± 0.5* 2.3 ± 0.2
Heart rate [beats/minute] 324 ± 20 290 ± 19* 297 ± 22
HbA1c [%] 5.9 ± 0.8 10.9 ± 1.8* 10.6 ± 2.4*
Total Carnitine [nmol/ml] 54.6 ± 6.1 59.3 ± 9.7 70.2 ± 11.3
Free Carnitine [nmol/ml] 43.7 ± 1.4 19.1 ± 1.3* 54.8 ± 4.4
FFA [meq./l] 0.26 ± 0.11 0.54 ± 0.33* 0.41 ± 0.19*
*Different from control p < 0.01
LVM/BW is the ratio of left ventricular mass/total body mass  [gm/kg] measured at baseline 2,6,10 and 18 weeks Figure 2
LVM/BW is the ratio of left ventricular mass/total body mass 
[gm/kg] measured at baseline 2,6,10 and 18 weeks. The val-
ues are mean ± SD. * indicates values that differ from control 
values p < 0.05.Cardiovascular Diabetology 2006, 5:2 http://www.cardiab.com/content/5/1/2
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correlated directly with the free carnitine levels (r = 0.41,
p < 0.0001), and inversely to HbA1c (r = -0.34, p =
0.0002) with Stepwise regression indicating that free car-
nitine had the greatest influence upon the heart rate.
Discussion
Cardiac function in rats is altered in association with
hyperglycemia [3-5]. The resting heart rates of STZ-D rats
have been noted to be reduced. This finding has been
unexplained, but the generally accepted mechanism is
diabetic neuropathy [13-15]. Hyperglycemia is believed
to cause peripheral nerve dysfunction [6]. The animals
reported in this study had diabetes induced at 26 weeks of
life and had an immediate reduction of their resting heart
rates after 2 weeks of hyperglycemia. We have previously
shown in Wistar rats that hyperglycemia onset at 26 weeks
of age does not induce altered peripheral nerve function
for the next 6 months [7]. Moreover, those with altered
peripheral nerve function at 26 weeks do not improved in
response to carnitine supplementation after 26 weeks
[16]. The decline in heart rate of the diabetic animals pro-
gressed at measures 6 and 10 weeks after streptozotocin
induced diabetes (figure 1). Between the 10 week and 18
week measurements, 12 of the 32 animals in this group
died, and the mean heart rate for the remaining members
of this group increased but continued to be less than the
control animals at 18 weeks. It is interesting to note that
the diabetic animals that died between 10 and 18 weeks
were those with the lowest free carnitine levels and heart
rates at the 10 week measurement. This finding suggests
that severely reduced carnitine levels may have contrib-
uted to the demise of those animals. Although the surviv-
ing diabetic animals without carnitine supplementation
at 18 weeks continued to have heart rates less than the
normal control animals, their heart rates and carnitine
levels were closer to normal (figure 1).
The myocardium utilizes both glucose and fatty acids for
energy metabolism. An abnormality in myocardial energy
metabolism [17] is a reported factor in the development
of diabetes-induced heart dysfunction. It has been noted
that the myocardium of STZ-D rats has reduced glucose
transport [18], and oxidation [19], as well as reduced fatty
acid oxidation [20] and reduced ATP production [21].
Under usual circumstances, fatty acid oxidation accounts
for 60% – 70%, glucose 40% – 30% of myocardial energy
supply. Under aerobic conditions fatty acids are the pre-
ferred energy substrate for the heart [22]. The transport of
long chain fatty acids across the mitochondrial membrane
to the site of beta-oxidation is dependent on carnitine
[23]. The importance of carnitine has been demonstrated
in clinical studies showing myocardial carnitine defi-
ciency to be associated with biventricular hypertrophy
[24] and cardiomyopathy [25]. Carnitine deficiency has
been reported in subjects with type 1 diabetes [28]. The
likely mechanism is excessive urinary loss in subjects with
high blood glucose levels and excessive urine volume,
which contains large quantities of organic acids as carni-
tine esters. Esterification of carnitine reduces the normal
renal tubular re-absorption of free carnitine, which
increases the daily loss. Reduced levels of carnitine limit
the availability of fatty acids in the mitochondria to gen-
erate ATP. It has been shown that proprionyl-carnitine
increases mitochondrial metabolism of pyruvate with
associated improvement of function in the isolated per-
fused heart of STZ-D rats [26]. The secondary substrate
available to generate ATP for myocardial function is glu-
cose. The availability of this substrate to the myocyte is
limited by the fixed dose of insulin administered each day
to insulin deficient animals. The evidence that these
important substrates had limited intracellular availability
was the elevated HbA1c [elevated extracellular glucose]
and elevated free fatty acids found in the diabetic animals.
When the hyperglycemic animals had higher free carni-
tine levels and lower levels of free fatty acids, their cardiac
function normalized. The carnitine treated and untreated
diabetic animal in this experiment had the same degree of
hyperglycemia as indicated by their HbA1c levels at the
end of the experiment. The dose of exogenous insulin for
both groups of animals was the same, but the free carni-
tine levels were higher in the STZ-D animals with oral car-
nitine supplementation. These animals also had lower
levels of extracellular free fatty acids. Those STZ-D rats
receiving oral carnitine had heart rates that did not differ
from the non-diabetic control animals. Dobutamine
stress in these diabetic animals produced an exaggerated
heart rate response only in those animals without carni-
tine supplementation. This observation suggests that
availability of energy substrate for the myocardium plays
an important role in heart rate regulation beyond auto-
nomic tone. Isolated peripheral nerve dysfunction
appears to be an unlikely explanation for the abnormal
heart rates at rest and with stress as noted in these STZ-D
rats. Centrally mediated or local SA node effects in the dia-
betic animals are possible explanations for these observa-
tions, but the corrective function of carnitine makes that
mechanism unclear.
The left ventricular mass/body weight ratio of the diabetic
animals was greater than that found in the control ani-
mals. This finding could be interpreted as indicative of left
ventricular hypertrophy in these animals. The left ventri-
cles of the diabetic animals, however, increased in size at
the same rate as those of the control animals; the apparent
difference in LVM/BW was the result of reduced body
weight gain in the diabetic animals. Failure to gain weight
is a common finding in diabetic animals, which results
from insufficient insulin for body mass increase. If LVM is
normally linked to increasing body mass, then the dia-
betic animals showed excessive increase in LVM duringCardiovascular Diabetology 2006, 5:2 http://www.cardiab.com/content/5/1/2
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the period of observation. This was confirmed by the
observation that the diabetic animals receiving oral carni-
tine supplementation gained body weight at the same
reduced rate as the carnitine deficient diabetic rats but
their LVM/BW was the same as the normal animals. Thus,
insulin limited diabetic animals with abundant free carni-
tine levels may have utilized increased fatty acid metabo-
lism to promote LVM increase in a normal relationship
with the animal body mass.
Oral carnitine supplementation in a group of STZ-D rats
with the same degree of hyperglycemia (HbA1c 10.9% vs.
10.6%) raised their serum carnitine level more than 2 fold
restoring the carnitine to control values (table 1). These
carnitine-replete animals had normal resting heart rates
after 8 weeks of supplementation and a normal heart rate
response to dobutamine stress after 16 weeks of supple-
mentation. The carnitine-supplemented STZ-D animals
also had an increase in left ventricular mass more consist-
ent with the increase in body weight noted in the control
animals. This finding suggests that the increase in ven-
tricular mass found in the carnitine deficient diabetic ani-
mals was excessive. Free fatty acid levels were greater and
the free carnitine levels were lower in the diabetic animals
than the control animals. Thus, it appears that a deficiency
of free carnitine can manifest as elevated free fatty acids,
suggesting a reduction of inter-cellular transport. Elevat-
ing free carnitine levels in insulin depleted diabetic ani-
mals with a fixed and relatively inadequate availability of
glucose as a myocardial fuel apparently corrected the
defects in myocardial function by providing more intrac-
ellular fatty acids as an energy substrate.
This experimental model appears to be an example of dia-
betic cardiac dysfunction caused by inadequate intracellu-
lar substrate in a milieu of excessive concentrations of
extra-cellular glucose and fatty acids. This phenomenon
can occur in clinical medicine. Carnitine levels should be
measured in diabetic patients to insure they have suffi-
cient levels to provide abundant substrate for cardiac
function, particularly during times of physical stress. Fur-
ther work is necessary to determine the contemporary
prevalence of carnitine deficiency in diabetic patients. The
therapeutic use of carnitine in this and other forms of car-
diomyopathy likewise needs evaluation.
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